Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - oxybutynin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - oxybutynin hydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

ethos consulting group - oxybutynin hydrochloride 2.5mg;  ;   - tablet - 2.5 mg - active: oxybutynin hydrochloride 2.5mg     excipient: crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose - oxybutynin ade is primarily indicated for the management of urgency and incontinence that characterise neurogenic bladder disorders and idiopathic detrusor instability.

New Zealand - English - Medsafe (Medicines Safety Authority)

ethos consulting group - oxybutynin hydrochloride 5mg;  ;   - tablet - 5 mg - active: oxybutynin hydrochloride 5mg     excipient: crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose - oxybutynin ade is primarily indicated for the management of urgency and incontinence that characterise neurogenic bladder disorders and idiopathic detrusor instability.

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - oxybutynin hydrochloride - tablets - 2.5 milligram - oxybutynin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - oxybutynin hydrochloride - tablets - 5 milligram - oxybutynin

Ireland - English - HPRA (Health Products Regulatory Authority)

syri limited, t/a thame laboratories - oxybutynin hydrochloride - oral solution - 2.5 mg/5ml - oxybutynin - anticholinergic as well as antispasmodic - urinary incontinence, urgency and frequency in the unstable bladder, whether due to neurogenic bladder disorders (detrusor hyperreflexia) in conditions such as multiple sclerosis and spina bifida, or to idiopathic detrusor instability (motor urge incontinence).

Ireland - English - HPRA (Health Products Regulatory Authority)

syri limited, t/a thame laboratories - oxybutynin hydrochloride - oral solution - 5 mg/5ml - oxybutynin - anticholinergic as well as antispasmodic - urinary incontinence, urgency and frequency in the unstable bladder, whether due to neurogenic bladder disorders (detrusor hyperreflexia) in conditions such as multiple sclerosis and spina bifida, or to idiopathic detrusor instability (motor urge incontinence).

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - oxybutynin hydrochloride - tablet - 2.5 milligram(s) - drugs for urinary frequency and incontinence; oxybutynin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - oxybutynin hydrochloride - tablet - 5 milligram(s) - drugs for urinary frequency and incontinence; oxybutynin